Forty percent of respondents had skipped a medical test or treatment to save on costs, and 32% had skipped filling a prescription (or took less medication than prescribed) because of costs.
NORC at the University of Chicago, together with the West Health Institute, released the results of a survey of American adults concerning their attitudes toward healthcare. They found that “healthcare costs have a significant and enduring impact on financial health.”
The survey was conducted among 1302 adults—providing a sample coverage of approximately 97% of US households—between February 15 and February 19 of this year using the AmeriSpeak Panel.
In the past year:
Other Americans reported going without care in order to save money, 40% of respondents had skipped a medical test or treatment to save on costs, and 32% had skipped filling a prescription (or took less medication than prescribed) because of costs.
Among those who had skipped a test or treatment, 60% said that they were afraid of the cost of a serious illness, while only 47% said that they were afraid of getting a serious illness itself. According to the report’s authors, these fears about the cost of treatment are often based on experience; more respondents who had negative financial impacts from previous healthcare costs (56%) feared paying for care than those who had not had previous experiences with financial hardship from healthcare costs (23%).
“It’s shocking and unacceptable that medical bills strike more fear in the hearts of Americans than serious illness,” said Shelley Lyford, president and CEO of West Health Institute, in a statement. “Americans are paying more for healthcare than they should and getting less than they deserve. Bold action is required to lower the sky-high cost of healthcare. The very health and wealth of our nation and its people are at stake.”
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
January 11th 2025Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.